首页|健艾康浓缩丸联合cART使用对HIV感染者肠道及其菌群的影响

健艾康浓缩丸联合cART使用对HIV感染者肠道及其菌群的影响

扫码查看
目的 研究健艾康浓缩丸联合cART对HIV感染者肠道的影响.方法 纳入HIV感染者26例,试验组13例给予健艾康浓缩丸+cART,对照组13例给予健艾康浓缩丸安慰剂+cART,连续治疗48周.收集两组血液和粪便,通过细胞学检查、16SrRNA高通量测序、短链脂肪酸及肠黏膜损伤标志物测定并进行分析.结果 试验组治疗后CD4+CD45RO+(269.77±57.78)表达水平较前(178.46±83.26)升高(P<0.01),CD4+CCR5+(19.08±5.95)较前(10.46±9.98)升高(P<0.05),CD4+CXCR4+(174.77±63.23)较前(244.46±89.38)降低(P<0.05);对照组治疗后 CD4/CD8 细胞比值(0.81±0.37)较前(0.52±0.25)升高(P<0.05),CD4+CD45RO+(313.15±95.04)较前(195.38±77.56)升高(P<0.01).在属水平,试验组绿脓杆菌属(Pseudomonas)、魏斯菌属(Weissella)、小链杆菌属(Catenibacterium)、放线菌属(Actinomyces)比例高于对照组(P<0.05),试验组泰泽雷拉菌属(Tyzzerella 4)比例低于对照组(P<0.05).试验组除乙酸外其余短链脂肪酸水平低于对照组(P>0.05),试验组外周血肠黏膜损伤标志物含量均低于对照组(P>0.05).结论 经48周治疗后两组HIV感染者肠道存在一定差异.相较于仅用cART,联合健艾康浓缩丸对免疫重建起到协同作用,联合治疗能潜在上调益生菌比例,具有降低肠黏膜损伤风险的趋势.
Effect of Jianaikang concentrated pill combined with cART on the intestinal and intestinal flora of patients with HIV
Objective To study the effect of Jianaikang concentrated pill combined with antiretroviral therapy(cART)on the intestinal tract of patients with HIV.Methods A total of 26 patients with HIV were enrolled.13 patients in the test group were administered Jianaikang concentrated pill+cART,and 13 patients in the control group received Jianaikang concentrated pill placebo+cART,and all the patients were treated for 48 weeks.The blood and stool of the two groups were collected and analyzed by cytological examination,16SrRNA high-throughput sequencing,and short-chain fatty acids and intestinal mucosal injury markers.Results In the test group,the post-treatment expression level of CD4+CD45RO+(269.77±57.78)was higher than at pre-treatment(178.46±83.26)(P<0.01).Additionally,the post-treatment expression level of CD4+CCR5+(19.08±5.95)was higher than at pre-treatment(10.46±9.98)(P<0.05).Conversely,the post-treatment CD4+CXCR4+(174.77±63.23)was lower than that at pre-treatment(244.46±89.38)(P<0.05).In the control group,the post-treatment CD4/CD8 ratio(0.81±0.37)was higher than at pre-treatment(0.52±0.25)(P<0.05),and the post-treatment CD4+CD45RO+(313.15±95.04)was higher than at pre-treatment(195.38±77.56)(P<0.01).At the genus level,the proportions of Pseudomonas,Weissella,Catenibacterium,and Actinomyces in the test group were higher than those in the control group(P<0.05),whereas the proportion of Tyzzerella 4 in the test group was lower than that in the control group(P<0.05).The levels of all short-chain fatty acids,except for acetic acid,in the test group were lower than those in the control group(P>0.05),and the levels of all peripheral intestinal mucosal injury markers in the test group were lower than those in the control group(P>0.05).Conclusions After 48 weeks of treatment,the intestinal tract of the two groups of patients with HIV exhibited distinct differences.Compared with cART alone,combined treatment with Jianaikang concentrated pill produced a synergistic effect on immune reconstruction.Combination therapy can potentially increase the proportion of probiotics and showed a trend toward reducing the risk of intestinal mucosal injury.

jianaikang concentrated pillHIVintestinal microbiotashort-chain fatty acidsintestinal mucosal injury markers

杨琴、杨欣怡、彭鑫、刘晶晶、王玉璐、兰燕玲、苗丁山、苏琛

展开 >

成都中医药大学,成都 610075

四川省中医药科学院,成都 610041

健艾康浓缩丸 艾滋病病毒 肠道菌群 短链脂肪酸 肠道黏膜损伤标志物

四川省中医药管理局科学技术研究专项

2023MS224

2024

中国艾滋病性病
中国性病艾滋病防治协会

中国艾滋病性病

CSTPCD北大核心
影响因子:1.292
ISSN:1672-5662
年,卷(期):2024.30(4)
  • 22